Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
September 30, 2021 09:25 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing
September 28, 2021 09:49 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial CEO William Stilley Invited to Participate in Maxim Group’s Virtual Panel Series Conference: “Disruptors in the Mental Health Space”
September 15, 2021 10:07 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
August 31, 2021 09:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
August 20, 2021 10:45 ET
|
Adial Pharmaceuticals, Inc
On track for trial completion in the first quarter of 2022 Adial to host business update call at 11AM Eastern today CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals,...
Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business Developments
August 20, 2021 09:40 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
August 12, 2021 14:50 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
August 10, 2021 09:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market
August 05, 2021 10:12 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...